In this project the research team wants to shed light on the mechanisms underlying inflammation in cystic fibrosis (CF) by studying the role of platelets. In addition to their known haemostatic role, platelets are also active in inflammation and its resolution. In CF, platelets are hyperactivated and malfunctioning, contributing to lung inflammation and slowing down the beneficial mechanisms of its resolution. The hypothesis behind this research is that reducing the contribution of platelets to lung inflammation is beneficial in people with CF. The aim of the project is therefore to determine how the treatment of platelets with selected molecules (resolvin D4 and E1) brings beneficial actions. To this end, platelets isolated from the blood of people with CF will be appropriately treated with resolvins and their ability to promote the resolution of inflammation will be monitored. These “ex vivo” studies on patient cells will be accompanied by preclinical “in vivo” studies on mouse models of pulmonary CF infection, in order to understand whether platelet modulation is also effective in experimental models of the disease. The results of these experiments will define the efficacy of resolvins as an antiplatelet strategy to reduce the pulmonary inflammatory burden in CF.